Eighteen isolates of a nonchromogenic, slowly growing, non-tuberculous species of the genus Mycobacterium were cultured from respiratory specimens obtained over the last eight years from 17 patients in the Netherlands. These isolates were grouped because they revealed a unique 16S rRNA gene sequence and were related to Mycobacterium xenopi. None of the 17 patients met the American Thoracic Society diagnostic criteria for non-tuberculous mycobacterial disease, which distinguishes the novel isolates from the related species, M. xenopi. A polyphasic taxonomic approach, including identification by biochemical and phenotypical analysis, hsp65 gene sequencing and PCR restriction enzyme pattern analysis, and sequence analyses of the rpoB gene and 16S-23S internal transcribed spacer supported the separate species status of the novel isolates. The name Mycobacterium noviomagense sp. nov. is proposed for the novel strains. The type strain is NLA000500338 T (5DSM 45145 T 5CIP 109766 T ). A more distinctive taxonomy of NTM is a prerequisite for the assessment of their clinical relevance.
Improved detection and identification techniques have triggered renewed interest in non-tuberculous mycobacteria (NTM) and their role as opportunistic pathogens. PCR techniques and 16S rRNA gene sequence analysis have brought to light a series of novel NTM species, however, the clinical relevance of these species is not always clear (Tortoli, 2003; Tortoli et al., 2001; Griffith et al., 2007) .
NTM infections present predominantly as chronic pulmonary disease, although extrapulmonary and disseminated infections have also been described (Griffith et al., 2007) . Local immunosuppression due to pre-existing pulmonary disease and systemic immunosuppression, e.g. in haema-tological malignancy, immunosuppressive medication and HIV/AIDS, have been identified as predisposing factors (Griffith et al., 2007) for NTM infections. Infection has to be differentiated from contamination and pseudo-infection, characterized by the recovery of single NTM isolates from the respiratory or digestive tract without signs of disease (Griffith et al., 2007; Portaels, 1995) . Their ubiquitous presence in the environment, survival in flowing water systems and resistance to disinfectants implies that NTM often represent laboratory or medical equipment contamination (Griffith et al., 2007; Portaels, 1995; van Klingeren & Pullen, 1993) . The diagnostic criteria proposed in a Statement by the American Thoracic Society (ATS) are designed to differentiate between true infection and pseudo-infection or contamination, based on clinical, radiological and microbiological features (Griffith et al., 2007) .
This study describes the grouping of 18 previously unknown Mycobacterium isolates with identical 16S rRNA gene sequences and with a high degree of gene sequence similarity to strains of Mycobacterium xenopi. As other features of these novel strains were highly distinct Abbreviations: ATS, American Thoracic Society; ITS, internal transcribed spacer; NTM, non-tuberculous mycobacteria.
The GenBank/EMBL/DDBJ accession numbers 16S rRNA, 16S-23S ITS 1 and 2, hsp65 and rpoB gene sequences of strain NLA000500338 T are EU239955, EU439248, EU439249, EU600390 and EU810775, respectively Phylogenetic trees based on hsp65 and rpoB gene sequences of selected mycobacterial species are available as supplementary material with the online version of this paper. from M. xenopi and the clinical relevance differed significantly between the new isolates and M. xenopi, the 18 isolates are proposed to represent a novel species of the genus Mycobacterium.
The 18 novel isolates were acquired from pulmonary samples (13 from sputum, 4 from broncho-alveolar lavage fluid and 1 from a post-mortem lung biopsy) of 17 patients in the Netherlands between January 1999 and January 2007. To determine clinical relevance, we examined the medical records of all 17 patients; their baseline characteristics are displayed in Table 1 . The predominance of male patients, mean age and history of chronic pulmonary disease are comparable with previous NTM studies (Griffith et al., 2007; Henry et al., 2004) . None of the patients had clinical and radiographic features suggestive of mycobacterial lung disease; one was systemically immunocompromised due to HIV co-infection. The post-mortem lung biopsy sample showed histological features of bronchopneumonia and invading bacteria, without features of mycobacterial disease such as granuloma formation. All patient samples were negative for acid-fast bacilli on direct microscopy which suggested the presence of a low number of NTM in the original sample or contamination after sample division for culture and microscopy. Although follow-up sputum cultures were performed for 16 patients, only one patient produced another culture that was positive for the novel strains. All others had a single positive culture. Based on these findings, none of the patients from whom the novel strains were isolated met the ATS criteria for pulmonary NTM disease (Griffith et al., 2007) . Good clinical response to non-antimycobacterial regimes, the subsequent establishment of alternative diagnoses and the observed spontaneous conversion to negative cultures suggested that the novel strains were not the causative agent of these patients' symptoms. The novel strains therefore seem to have no clinical relevance, which distinguishes them from phylogenetically related, but more pathogenic species such as M. xenopi and Mycobacterium heckeshornense (Griffith et al., 2007; Roth et al., 2000; van Ingen et al., 2008) .
Two patients received antituberculosis treatment for an average period of 10 weeks, after a presumptive diagnosis of TB. Treatment of patients not meeting the ATS diagnostic criteria is potentially harmful to patients in terms of adverse effects and costs (van Crevel et al., 2001) .
Geographical clustering of the patients was observed, favouring the south-east of the Netherlands, in adjacent areas of the Limburg (7 cases), Gelderland (5 cases) and Noord-Brabant (2 cases) provinces. This clustering suggested the presence of the novel strains in specific local environments or tap water. Since the clustering was seen geographically, but not over time, contamination from medical machinery or the laboratories involved seemed less likely.
All of the novel isolates were subjected to laboratory diagnosis by the National Mycobacteria Reference Laboratory of the National Institute for Public Health and the Environment (RIVM). The RIVM provides molecular identification, drug susceptibility testing and epidemiological typing of mycobacterial isolates for all healthcare institutions in the Netherlands.
Biochemical identification and HPLC analysis of cell-wall mycolic acid content were performed using previously described approaches (Lévy-Frébault & Portaels, 1992; Centers for Disease Control and Prevention, 1996) . Eight isolates (4 M. xenopi, 4 of the novel strains) were subjected to biochemical testing. The results are detailed in Table 2 . Morphologically, two patterns were clearly discernible. On Middlebrook 7H10 media, the M. xenopi isolates were scotochromogenic, showing yellow pigmentation, whereas colonies of the novel species were smaller and nonchromogenic. All M. xenopi isolates grew at 45 u C, as previously reported (Torkko et al., 2000) , but the novel strains were unable to grow at this temperature (Table 2) . Biochemically, the novel isolates were indistinguishable from the cluster comprising M. xenopi, Mycobacterium botniense and M. heckeshornense, with negative results for urease, Tween 80 hydrolysis, niacin production, nitrate reductase, acid phosphatase and semi-quantitative catalase. HPLC of the novel isolates revealed a pattern characterized by one early and one late cluster of peaks, a profile similar to that of M. xenopi, M. heckeshornense and M. botniense (Fig. 1) . The HPLC mycobacterium library (available online at http:// www.MycobacToscana.it) was used for this comparison.
Susceptibility testing was performed for eleven of the novel isolates from eleven patients using the agar dilution method (van Klingeren et al., 2007) . For the novel isolates, we recorded in vitro resistance to rifampicin (MIC 2 mg l 21 ), resistance or intermediate susceptibility to ethambutol (MIC 10-20 mg l 21 ) and intermediate susceptibility to isoniazid (MIC 0.5-1 mg l 21 ). The novel species proved susceptible in vitro to streptomycin, cycloserine, prothionamide, amikacin, ciprofloxacin, clofazimine, clarithromycin and rifabutin. The drug susceptibility pattern for the novel isolates differed slightly from clinical isolates of M. xenopi tested at RIVM which were mostly susceptible, in vitro, to rifampicin (MIC 0.5-1 mg l 21 ). These results for M. xenopi are in accordance with previous reports (Dauendorffer et al., 2002) .
For molecular identification, sequencing of the full 16S rRNA gene and 16S-23S internal transcribed spacer (ITS), partial rpoB and hsp65 genes, and PCR restriction enzyme pattern analysis (PRA) of the hsp65 gene were performed using previously described methods (Kim et al., 1999; Roth et al., 1998; Springer et al., 1996; Telenti et al., 1993) . The sequences obtained were compared with the GenBank/EMBL (NCBI, http://www.ncbi.nlm.nih.gov) gene sequence databases.
The full 16S rRNA gene sequence for the novel species showed 96 % sequence similarity with that of M. xenopi and was 97 % similar to those of M. heckeshornense and Mycobacterium shimoidei. A sequence difference of 1 % has been proposed in the literature as the threshold for the designation of a novel species (Hall et al., 2003; Tortoli, 2003) .
The full 16S rRNA gene sequence of the novel strains was aligned with those of reference strains of the closest related mycobacteria using CLUSTAL_X software (Thompson et al., 1997) . The resulting topology and tree, inferred by neighbour-joining and visualized using the LOFT software package (van der Heijden et al., 2007) were evaluated by bootstrap analyses based on 1000 resamplings (Fig. 2) .
Analysing only the hypervariable region A of the 16S rRNA gene (151 bp), we found a 100 % match in the GenBank/ EMBL database to a strain designated 'most closely resembling M. xenopi', as reported by Hall et al. (2003) . Analysis of the phenotypic and genetic characteristics of the novel species ( , 2007) . Bootstrap values are indicated at the nodes. the major city in the endemic region in the Netherlands and the location of the reference hospital; current name: Nijmegen).
Acid-fast and Gram-positive rods. Colonies are nonchromogenic and appear after 4 weeks of culture at 37 u C, no growth occurs at 45 u C. Negative in tests for urease, Tween 80 hydrolysis, niacin production, nitrate reductase, acid phosphatase and semi-quantitative catalase. Can be readily identified by its unique rRNA gene sequences.
The type strain, NLA000500338 T (5DSM 45145 T 5CIP 109766 T ), was recovered from sputum.
